Development of new medical treatment for epithelial ovarian cancer recurrence.
BRCA mutation
Ovarian cancer
PARP inhibitors
chemotherapy
recurrence
Journal
Gland surgery
ISSN: 2227-684X
Titre abrégé: Gland Surg
Pays: China (Republic : 1949- )
ID NLM: 101606638
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
entrez:
21
9
2020
pubmed:
22
9
2020
medline:
22
9
2020
Statut:
ppublish
Résumé
Epithelial ovarian cancer (EOC) is the scariest gynaecological cancer. Many advances have been done with evolving knowledge, leading to the introduction of new drugs, most in maintenance setting. The antiangiogenic Bevacizumab and the three approved PARP-inhibitors-olaparib, niraparib and rucaparib-are gradually improving PFS of patients with EOC, with initial effects on OS too. But recurrence is still a heavy sentence and lethality continues to be high. Ovarian cancer is a complex disease, with different clinical presentation, histological aspect, and molecular expression, leading to disappointing results, when using a single drug. Implementation of biobanking and analysis of patients' tumour samples, before starting a treatment, could be a promising way to better understand molecular aspects of this disease, to identify markers predictive of response and to allow a better use of experimental drugs, as immunomodulators, targeted therapies, and combinations of these, to fight tumour growth and clinical progression. We reviewed the literature on the updated treatments for recurrent ovarian cancer, summarizing all the available drugs and combinations to treat patients with this diagnosis, and focusing the attention on the new approved molecules and the contemporary Clinical Trials, investigating new target therapies and new associations.
Identifiants
pubmed: 32953630
doi: 10.21037/gs-20-413
pii: gs-09-04-1149
pmc: PMC7475356
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1149-1163Informations de copyright
2020 Gland Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs-20-413). The series “Ovarian Cancer Recurrence” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.
Références
Cancer Res. 2011 Sep 1;71(17):5626-34
pubmed: 21795476
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Ann Surg Oncol. 2016 May;23(5):1660-5
pubmed: 26714958
Trends Genet. 2013 Jul;29(7):394-402
pubmed: 23537585
Cancer Chemother Pharmacol. 2019 Oct;84(4):791-798
pubmed: 31375879
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2201-6
pubmed: 20133863
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Healthcare (Basel). 2019 Sep 19;7(3):
pubmed: 31546963
Int J Gynecol Cancer. 2019 May 2;:
pubmed: 31048403
J Clin Oncol. 2012 Jul 20;30(21):2654-63
pubmed: 22711857
Int J Gynecol Cancer. 2017 Feb;27(2):246-247
pubmed: 28114231
J Clin Oncol. 2017 Apr 1;35(10):1112-1118
pubmed: 28029313
Gynecol Oncol. 2019 Nov;155(2):186-191
pubmed: 31519320
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
J BUON. 2011 Jan-Mar;16(1):74-9
pubmed: 21674853
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Ann Oncol. 2017 Jun 1;28(6):1280-1287
pubmed: 28368437
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
Ann Oncol. 1997 Oct;8(10):963-8
pubmed: 9402168
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Clin Med Insights Oncol. 2016 Apr 25;10:35-41
pubmed: 27147900
Oncotarget. 2017 Jul 18;8(29):47154-47160
pubmed: 28454085
Int J Gynecol Cancer. 2016 May;26(4):661-70
pubmed: 26844612
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Cancer. 2017 Jul 15;123(14):2752-2761
pubmed: 28339098
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
J Clin Oncol. 2010 Jul 10;28(20):3323-9
pubmed: 20498395
Clin Cancer Res. 2014 Feb 1;20(3):764-75
pubmed: 24240112
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Ann Oncol. 2011 Jan;22(1):49-58
pubmed: 20643863
Gynecol Oncol. 2018 Mar;148(3):507-514
pubmed: 29352572
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
J Clin Oncol. 2015 Apr 20;33(12):1397-406
pubmed: 25779564
Lancet. 2003 Jun 21;361(9375):2099-106
pubmed: 12826431
Gynecol Oncol. 2010 Oct;119(1):32-7
pubmed: 20584542
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
Expert Rev Anticancer Ther. 2017 Dec;17(12):1147-1158
pubmed: 29086618
Front Oncol. 2013 Sep 11;3:228
pubmed: 24062981
Gynecol Oncol. 2016 Oct;143(1):27-34
pubmed: 27546885
Lancet Oncol. 2018 Aug;19(8):1117-1125
pubmed: 30026000
Ann Oncol. 2011 Jan;22(1):39-48
pubmed: 20643862
Lancet Oncol. 2018 Aug;19(8):1126-1134
pubmed: 30026002
Cancer Treat Rev. 2019 Nov;80:101909
pubmed: 31629204
Gynecol Oncol. 2015 Aug;138(2):278-84
pubmed: 26049123
Gynecol Oncol. 2006 Jun;101(3):436-40
pubmed: 16325893
J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):428-32
pubmed: 25461683
Lancet. 2002 Aug 17;360(9332):505-15
pubmed: 12241653
Lancet Oncol. 2015 May;16(5):561-8
pubmed: 25882986
Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1198-1205
pubmed: 28387913
Lancet. 2016 Mar 12;387(10023):1066-1074
pubmed: 27025186
Ann Oncol. 2018 Aug 1;29(8):1784-1792
pubmed: 29767688
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Gynecol Oncol. 2017 Mar;144(3):486-490
pubmed: 28109627
Gynecol Oncol. 2015 Jan;136(1):130-5
pubmed: 25434634
Int J Oncol. 2009 Jan;34(1):79-87
pubmed: 19082480
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Expert Rev Anticancer Ther. 2010 Jan;10(1):81-8
pubmed: 20014888
J Natl Cancer Inst. 2014 May 19;106(6):dju089
pubmed: 24842883
J Clin Oncol. 2015 Nov 10;33(32):3836-8
pubmed: 26282651
Updates Surg. 2019 Sep;71(3):555-560
pubmed: 30094567
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
Gynecol Oncol. 2015 Jun;137(3):386-91
pubmed: 25818403
Cancer Treat Rev. 2012 Jun;38(4):272-83
pubmed: 21764518
Langenbecks Arch Chir. 1988;373(3):189-96
pubmed: 3288830
Clin Cancer Res. 2015 Apr 1;21(7):1574-82
pubmed: 25589624
Eur J Cancer. 2017 Jan;70:111-121
pubmed: 27914241
Ther Adv Med Oncol. 2017 Apr;9(4):253-267
pubmed: 28491146
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
Int J Gynecol Cancer. 2011 May;21(4):771-5
pubmed: 21543939
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Curr Pharm Des. 2019;25(22):2480-2490
pubmed: 31333115
Geburtshilfe Frauenheilkd. 2016 Feb;76(2):147-149
pubmed: 26941446
Eur J Cancer. 2009 Sep;45(13):2324-32
pubmed: 19515553
CA Cancer J Clin. 2011 May-Jun;61(3):183-203
pubmed: 21521830
Gynecol Oncol. 2015 Oct;139(1):10-6
pubmed: 26271155
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Lancet Oncol. 2014 Jul;15(8):799-808
pubmed: 24950985
Gynecol Oncol. 2019 Feb;152(2):243-250
pubmed: 30522700
Clin Cancer Res. 2016 Jul 1;22(13):3227-37
pubmed: 26842236
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Int J Gynecol Cancer. 2011 May;21(4):750-5
pubmed: 21543936
Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404
pubmed: 31685558
J Clin Oncol. 2006 Oct 10;24(29):4699-707
pubmed: 16966687
Br J Cancer. 2017 Mar 28;116(7):884-892
pubmed: 28222073
Curr Oncol Rep. 2008 Nov;10(6):519-23
pubmed: 18928667
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11
pubmed: 21300883
J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63
pubmed: 17105988
Ann Surg Oncol. 2017 Dec;24(Suppl 3):630
pubmed: 29094252